Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Lilly is set to acquire Centessa Pharmaceuticals, gaining ownership of its OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders. The pipeline was jointly discovered by Nxera and Centessa, with Nxera retaining a material economic interest in its future development and commercialization.
Lilly is acquiring Centessa Pharmaceuticals, obtaining its OX2R agonist pipeline. The pipeline aims to improve sleep-wake disorders. Nxera and Centessa jointly discovered the pipeline, with Nxera retaining economic interest. The acquisition includes cleminorexton, ORX142, and ORX489. Nxera is entitled to milestone payments and royalties. The company has a separate collaboration with Lilly to develop metabolic diseases treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.